95 episodes

Oncotarget is a bi-weekly, peer-reviewed, open-access biomedical journal covering research on all aspects of oncology

Oncotarge‪t‬ Oncotarget Podcast

    • Science
    • 5.0 • 2 Ratings

Oncotarget is a bi-weekly, peer-reviewed, open-access biomedical journal covering research on all aspects of oncology

    Trending with Impact: Machine Learning Used to Compare ALK Inhibitors

    Trending with Impact: Machine Learning Used to Compare ALK Inhibitors

    In February, 2021, researchers from Spain conducted a study published in Oncotarget, titled: “Head to head evaluation of second generation ALK inhibitors brigatinib and alectinib as first-line treatment for ALK+ NSCLC using an in silico systems biology-based approach.”

    This trending paper was authored by researchers practicing at the Hospital Germans Trias i Pujol, Takeda Farmacéutica España, Anaxomics Biotech, and Universitat Pompeu Fabra.

    The researchers used a computer simulated modeling system to highlight the strengths and weaknesses of two ALK inhibitors. They first began their study by characterizing the pathophysiology of ALK+ NSCLC after completing a detailed review of review papers published in PubMed between 2013 and 2018.
    Read the full study here: https://www.oncotarget.com/article/27875/text/

    The Trending with Impact series highlights Oncotarget publications attracting higher visibility among readers around the world online, in the news, and on social media—beyond normal readership levels.
    More from Trending with Impact: www.oncotarget.org/tag/trending-with-impact/

    About Oncotarget:

    Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

    To learn more about Oncotarget, please visit www.oncotarget.com or follow us:

    SoundCloud - @oncotarget
    Facebook - www.facebook.com/Oncotarget/
    Twitter - twitter.com/oncotarget
    LinkedIn - www.linkedin.com/company/oncotarget
    Instagram - www.instagram.com/oncotargetjrnl/
    YouTube - www.youtube.com/OncotargetYouTube
    Pinterest - www.pinterest.com/oncotarget/
    Reddit - www.reddit.com/user/Oncotarget/

    Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls

    Media Contact
    MEDIA@IMPACTJOURNALS.COM
    18009220957x105

    • 6 min
    Oncotarget: The First Study on CABYR Isoforms in Colorectal Cancer

    Oncotarget: The First Study on CABYR Isoforms in Colorectal Cancer

    In the cover paper of this week's issue of Oncotarget, titled: "The cancer testis antigens CABYR-a/b and CABYR-c are expressed in a subset of colorectal cancers and hold promise as targets for specific immunotherapy," researchers evaluate CABYR isoforms a/b and c mRNA expression in colorectal cancer in hopes of determining whether or not these proteins may be promising vaccine targets.
    Read the full study here: https://doi.org/10.18632/oncotarget.27897
    Oncotarget Volume 12, Issue 5: https://www.oncotarget.com/archive/v12/i5/

    About Oncotarget:

    Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

    To learn more about Oncotarget, please visit www.oncotarget.com or follow us:

    SoundCloud - @oncotarget
    Facebook - www.facebook.com/Oncotarget/
    Twitter - twitter.com/oncotarget
    LinkedIn - www.linkedin.com/company/oncotarget
    Instagram - www.instagram.com/oncotargetjrnl/
    YouTube - www.youtube.com/OncotargetYouTube
    Pinterest - www.pinterest.com/oncotarget/
    Reddit - www.reddit.com/user/Oncotarget/

    Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls

    Media Contact
    MEDIA@IMPACTJOURNALS.COM
    18009220957x105

    • 6 min
    Table of Contents: Oncotarget Volume 12, Issue #5

    Table of Contents: Oncotarget Volume 12, Issue #5

    Listen to short summaries of the latest oncology-focused research literature published in this week's issue of Oncotarget Volume 12, Issue 5.
    Click here for the complete issue: https://www.oncotarget.com/archive/v12/i5/

    Oncotarget Volume 12, Issue 5 features:

    Cover Paper: "The cancer testis antigens CABYR-a/b and CABYR-c are expressed in a subset of colorectal cancers and hold promise as targets for specific immunotherapy." https://doi.org/10.18632/oncotarget.27897

    Research Perspective: "Tumor mutational burden as a predictor of immunotherapy response in breast cancer." https://doi.org/10.18632/oncotarget.27877

    Research Paper: "STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells." https://doi.org/10.18632/oncotarget.27884

    Research Paper: "Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology." https://doi.org/10.18632/oncotarget.27894

    Research Paper: "Mutational profile of skin lesions in hepatocellular carcinoma patients under tyrosine kinase inhibition: a repercussion of a wide-spectrum activity." https://doi.org/10.18632/oncotarget.27891

    Research Paper: "Development of a ghrelin receptor inverse agonist for positron emission tomography." https://doi.org/10.18632/oncotarget.27895

    Research Paper: "Global DNA hypermethylation pattern and unique gene expression signature in liver cancer from patients with Indigenous American ancestry." https://doi.org/10.18632/oncotarget.27890

    Research Paper: "Fine–mapping of two differentiated thyroid carcinoma susceptibility loci at 2q35 and 8p12 in Europeans, Melanesians and Polynesians." https://doi.org/10.18632/oncotarget.27888

    Research Paper: "Quantitative proteome profiling stratifies fibroepithelial lesions of the breast." https://doi.org/10.18632/oncotarget.27889

    About Oncotarget:

    Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

    To learn more about Oncotarget, please visit www.oncotarget.com or follow us:

    SoundCloud - @oncotarget
    Facebook - www.facebook.com/Oncotarget/
    Twitter - twitter.com/oncotarget
    LinkedIn - www.linkedin.com/company/oncotarget
    Instagram - https://www.instagram.com/oncotargetjrnl/
    YouTube - https://www.youtube.com/OncotargetYouTube
    Pinterest - www.pinterest.com/oncotarget/
    Reddit - www.reddit.com/user/Oncotarget/

    Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls

    Media Contact
    MEDIA@IMPACTJOURNALS.COM
    18009220957x105

    • 8 min
    Trending with Impact: Crosstalk In the Tumor Microenvironment

    Trending with Impact: Crosstalk In the Tumor Microenvironment

    A review paper published this month in Oncotarget by researchers from the University of Modena and Reggio Emilia in Italy and the Sulaiman AlRajhi Medical School in Saudi Arabia is trending, and titled, “Cancer stem cells and macrophages: molecular connections and future perspectives against cancer.”
    (Read the paper here: https://www.oncotarget.com/article/27870/text/)

    Two authors of this review paper, Dr. Beatrice Aramini and Dr. Valentina Masciale, provide an overview of their research on the complex crosstalk between cancer stem cells and macrophages, and potential anti-cancer strategies for future studies.

    The Trending with Impact series highlights Oncotarget publications attracting higher visibility among readers around the world online, in the news, and on social media—beyond normal readership levels.
    (More from Trending with Impact: https://www.oncotarget.org/tag/trending-with-impact/)

    About Oncotarget:

    Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

    To learn more about Oncotarget, please visit www.oncotarget.com or connect with us on:

    SoundCloud - @oncotarget
    Facebook - www.facebook.com/Oncotarget/
    Twitter - twitter.com/oncotarget
    LinkedIn - www.linkedin.com/company/oncotarget
    Pinterest - www.pinterest.com/oncotarget/
    Reddit - www.reddit.com/user/Oncotarget/

    Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls

    Media Contact
    MEDIA@IMPACTJOURNALS.COM
    18009220957x105

    • 9 min
    Oncotarget Podcast Episodes: The Latest in Oncology-Focused Research

    Oncotarget Podcast Episodes: The Latest in Oncology-Focused Research

    Hundreds of scientific studies, reviews, and analyses are being published from around the world at any given time. This can make reading the latest research literature a time consuming task—depending, of course, on the quantity of papers one hopes to consume. As a tool to help alleviate this important undertaking, many researchers have taken to listening to one of the top open-access podcasts of 2020 and 2021: The Oncotarget Podcast.

    After a paper is published, it is added to an enhanced post-publication service provided by Oncotarget, in an effort to help authors reach a wider audience. This podcast series is another way to widely distribute the research that is published with free access by Oncotarget. Oncotarget Podcast episodes regularly include audio readings, press releases, and interviews with authors about their latest and trending papers published by Oncotarget. Player.fm (https://player.fm/podcasts/open-access) rated the Oncotarget Podcast on their lists of Best Open Access Podcasts of 2020 and 2021.

    Oncotarget, and Impact Journals as a whole, is constantly expanding the definition of open-access to include a wide variety of accessibility-based audio and visual media to support researchers and readers with disabilities. Creators of the Oncotarget Podcast hope that offering audible renderings of literature from Oncotarget.com, and of blog posts from Oncotarget.org and Oncotarget.net, will be helpful for the vision impaired community.

    Stay up-to-date with all of the latest oncology-focused research literature published by Oncotarget by subscribing to the Oncotarget Podcast, which can be found on Soundcloud, Apple, Stitcher, and Blubrry podcast streaming services.

    About Oncotarget:

    Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

    To learn more about Oncotarget, please visit www.oncotarget.com or connect with:

    SoundCloud - @oncotarget
    Facebook - www.facebook.com/Oncotarget/
    Twitter - twitter.com/oncotarget
    LinkedIn - www.linkedin.com/company/oncotarget
    Pinterest - www.pinterest.com/oncotarget/
    Reddit - www.reddit.com/user/Oncotarget/

    Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls

    Media Contact
    MEDIA@IMPACTJOURNALS.COM
    18009220957x105

    • 2 min
    Blagosklonny - The Goal Of Geroscience Is Life Extension

    Blagosklonny - The Goal Of Geroscience Is Life Extension

    Dr. Mikhail V. Blagosklonny, M.D., Ph.D., Editor-in-Chief of Oncotarget, and Professor, at Roswell Park Cancer Institute, published "The goal of geroscience is life extension" which was selected as the Featured Cover Paper for Volume 12 Issue 3 and reported that although numerous drugs seemingly extend healthspan in mice, only a few extend lifespan in mice and only one does it consistently. Some of them, alone or in combination, can be used in humans, without further clinical trials.

    Dr. Mikhail V. Blagosklonny from The Roswell Park Cancer Institute said, "Although we do not know everything about aging, we now know enough to start its pharmacologic suppression using clinically approved drugs."

    Published in 2010, these opening words of the paper entitled "Increasing healthy lifespan by suppressing aging in our lifetime: preliminary proposal" are still relevant today.

    Hyperfunction of these signaling pathways directly drive all age-related diseases, which are manifestations of aging. We just need clinically available inhibitors of these signaling pathways to extend both healthspan and lifespan, by slowing aging.

    A mere extension of healthspan is not enough: drugs that fail to extend lifespan in mice will fail to extend lifespan in humans, if used as a monotherapy.

    Yet, in rational combinations with life-extending drugs, "healthspan-only" drugs may extend lifespan further.

    In this Oncotarget publication, Dr. Blagosklonny reviews drugs that extend lifespan and healthspan in mammals, in contrast to those that may affect only healthspan without lifespan, and discusses how to proceed with clinical application of lifespan-extending drugs.

    Blagosklonny concluded in their Oncotarget Research Perspective, "If we want to live longer, we have no choice, but to use drugs such as rapamycin, which extends life in short-lived mammals and is approved for humans use. After all, humans are mammals, and there is no reason to think that they will not work in humans."

    Please note: This review is intended for a professional audience. This article does not represent medical advice or recommendations to patients. The media should exercise caution and seek expert medical advice for interpretation, when referring to this article. Medical doctors interested in this topic may e-mail the author at Blagosklonny@rapalogs.com or follow on Twitter @Blagosklonny

    Sign up for free Altmetric alerts about this article

    DOI - https://doi.org/10.18632/oncotarget.27882

    Full text - https://www.oncotarget.com/article/27882/text/

    Correspondence to - Mikhail V. Blagosklonny - Blagosklonny@oncotarget.com, Blagosklonny@rapalogs.com

    Keywords - aging, longevity, rapamycin, mTOR, metformin

    About Oncotarget

    Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology.

    To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with:

    SoundCloud - https://soundcloud.com/oncotarget
    Facebook - https://www.facebook.com/Oncotarget/
    Twitter - https://twitter.com/oncotarget
    LinkedIn - https://www.linkedin.com/company/oncotarget
    Pinterest - https://www.pinterest.com/oncotarget/
    Reddit - https://www.reddit.com/user/Oncotarget/

    Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls

    Media Contact
    MEDIA@IMPACTJOURNALS.COM
    18009220957x105

    • 2 min

Customer Reviews

5.0 out of 5
2 Ratings

2 Ratings

Top Podcasts In Science